KẾT QUẢ ĐIỀU TRỊ BƯỚC MỘT UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ DI CĂN NÃO CÓ ĐỘT BIẾN EGFR BẰNG OSIMERTINIB

Abstract

Objectives: Describe some clinical and subclinical characteristics of patients and evaluate the results of first line Osimertinib in untreated EGFR-mutant non-small cell lung cancer patients with brain metastasis in K Hospital from 4/2019 to 7/2023.  Patients and methods: A retrospective study on 38 untreated EGFR-mutant non small cell lung cancer patients with brain metastasis were treated with Osimertinib as the first line in K Hospital from 4/2019 to 7/2023. Results: 38 patients enrolled, the average age was 63.61 ± 9.30 years with the ratio of female/male was 2.46. The rate of systemic ORR was 84.2%; the median PFS and iPFS was 14.97 months and 28.63 months respectively. The average OS was  37.32±3.37 months and 30-month survival rate was 62%. In PS 0-1 subgroup, the size of the largest BMs < 3cm subgroup had a longer median PFS and iPFS compared to PS =2, the size of the largest BMs> 3cm subgroup (p <0.005). No difference in PFS and iPFS was observed among the number of BMs, the extracranial lesions, EGFR mutation type and the type of therapy. The most commonly reported adverse events due to any cause were rash (31.5%), diarrhea (28.9%) and dry skin (21%). One patient had to reduce the dosage due to the cardiac adverse effect. No adverse events of grade 3 or higher were observed in our study. Conclusion: The therapeutic of Osimertinib as the first line is highly effective and safe in EGFR-positive non-small cell lung cancer with brain metastasis.